hairy cell leukaemia


Also found in: Encyclopedia.
A low-grade B-cell leukaemia comprising 2% of adult leukaemia, commonly affecting men—male:female ratio, 4:1—age 50-55, leading to progressive pancytopenia; 10% have platelet counts of < 20 x 109/L—US: < 20,000/mm3—20% have thrombocytosis; 1-80% of nucleated RBCs are hairy.
The ‘classic’ or Japanese form—which comprises most cases of HCL—responds better to therapy than the non-classic or variant form
Lab Increased acid phosphatase, especially isoenzyme 5—increased in bone metastases and in Gaucher’s disease
Management First-line therapy: purine analogues 2’-deoxycoformycin (pentostatin) and 2-chlorodeoxyadenosine (cladribine)
Cause of death Infections, gram-negative bacteria, atypical mycobacteria, fungi

hairy cell leukaemia

A rare disease featuring overgrowth of B .LYMPHOCYTES usually in men between 40 and 60 years of age. The lymphocytes show prominent hair-like projections. There is a profound drop in the numbers of all blood cells and the spleen, which is the site of the bulk of the abnormal lymphocytes, is enlarged. Treatment is by spleen removal (splenectomy) and the use of drugs such as alpha-INTERFERON and deoxycoformycin.
Mentioned in ?
References in periodicals archive ?
AstraZeneca, a UK-based pharmaceutical company, and MedImmune, its global biologics research and development arm, announced on Friday that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
AstraZeneca's Lumoxiti (moxetumomab pasudotox-tdfk) gains USFDA approval for certain patients with relapsed or refractory hairy cell leukaemia
The data regarding the influence of analogues of purine nucleosides on reproduction functions results undoubtedly from the epidemiology of hairy cell leukaemia (HCL).
Intrinsic apoptosis pathway in fallopian tube epithelial cells induced by cladribine
The 40-year-old has been diagnosed with hairy cell leukaemia - a chronic blood cancer for which there is currently no cure.
'Leukaemia diagnosis is not death sentence' Last year about 20 people were diagnosed with hairy cell leukaemia in the North East. Health Reporter HELEN RAE speaks to a woman who was one of those told she had the rare blood cancer My Health
Ferdie Stern passed away peacefully in Durban on 1 June 2010 in his 91st year, a victim of hairy cell leukaemia. His parents, Simon and Bertha, had emigrated from a small village, Rohatten, in Austria and settled in Dordrecht in the Eastern Cape where they farmed.
Ferdie Stern
Jim was first diagnosed with the rare blood cancer, hairy cell leukaemia, in 2004.
Record hero's cancer battle; Brave cop faces second fight
Chronic Lymphoid leukaemia and hairy cell leukaemia due to chronic exposure to benzene: report of three cases.
Concentrations of Organochlorines Related to Titers to Epstein-Barr Virus Early Antigen IgG as Risk Factors for Hairy Cell Leukemia
Innate is licensing the US and EU commercial rights to recently FDA-approved Lumoxiti (moxetumomab pasudotox) for hairy cell leukaemia (HCL).
United Kingdom : AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
M2 EQUITYBITES-September 17, 2018-AstraZeneca announces US FDA approval of Lumoxiti to treat hairy cell leukaemia
AstraZeneca announces US FDA approval of Lumoxiti to treat hairy cell leukaemia
M2 PHARMA-September 17, 2018-AstraZeneca announces US FDA approval of Lumoxiti to treat hairy cell leukaemia
AstraZeneca announces US FDA approval of Lumoxiti to treat hairy cell leukaemia
The differential diagnoses of PCL include B-cell chronic lymphocytic leukaemia, hairy cell leukaemia and marginal zone lymphomas with circulating lymphocytes.
Plasma cell leukaemia--an aggressive plasma cell dyscrasia
Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1).
Diagnosis of Splenic B-Cell Lymphomas in the Bone Marrow: A Review of Histopathologic, Immunophenotypic, and Genetic Findings
Around 21,500 people get leukaemia in the UK every year but fewer than 100 get the hairy cell leukaemia which attacked his body.
Athletics: I couldn't walk... but I knew I'd finish London marathon; our heroes Super-fit leukaemia victim has raised pounds 38,000 for charity COURAGE OF CANCER COP JIM

Medical browser ?
Full browser ?